Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Pain resulting directly or indirectly from the growth of malignant cells is one of the most common and distressing symptoms associated with cancer.62 Cancer-related pain occurs in approximately one-quarter of the patients at the time of diagnosis and early in the course of disease, in three-quarters of the patients with advanced disease, and in almost one-third of the patients on active therapy.10,15,62 It is estimated that almost one in two patients with cancer pain are sub-optimally treated.10

Source: The Journal of Pain - October 24, 2018 Category: Materials Science Authors: Neal Slatkin, Naim Zaki, Steven Wang, John Louie, Panna Sanga, Kathleen M. Kelly, John Thipphawong Source Type: research